Related Experiment Videos
Reduced expression of CDKN2a/P16INK4a in mycosis fungoides
K Peris1, G Stanta, M C Fargnoli
1Department of Dermatology, University of L'Aquila, Italy.
Abstract:
Alterations in the CDKN2a gene have been demonstrated in a wide range of human tumors including hematopoietic malignancies. To verify whether altered CDKN2a expression is involved in the pathogenesis of mycosis fungoides (MF), we examined mRNA expression in 20 patients with MF by RT-PCR and dot blot hybridization. CDKN2a mRNA expression was undetectable in 5 of the 20 patients (25%), intermediate in 13 (65%) and high in 2 (10%). Immunohistochemical studies, which were performed in ten patients, revealed that in the four patients showing no mRNA, p16INK4a was expressed in <1% of neoplastic lymphocytes whereas in the four patients with an intermediate mRNA level, specific nuclear staining was present in 1-25% of tumor cells. In the two patients with high levels of CDKN2a mRNA, >25% of neoplastic lymphocytes stained positively. No direct correlation between clinicopathological and molecular findings was evident in our patients. DNA mutational analysis revealed no alterations in a total of six patients examined. Our results indicate that the lack of CDKN2a expression, as found in 25% of the patients, may have a pathogenetic role in MF even though the absence of CDKN2a mRNA was not associated with point mutations or minor gene deletions.
Insights
Altered CDKN2a gene expression is implicated in mycosis fungoides (MF) pathogenesis. In 25% of MF patients, CDKN2a mRNA was undetectable, suggesting a potential role in disease development.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Alterations in the CDKN2a gene are common in various human cancers.
- The role of CDKN2a in the pathogenesis of mycosis fungoides (MF) remains unclear.
Purpose of the Study:
- To investigate the expression of CDKN2a mRNA and its protein product (p16INK4a) in patients with mycosis fungoides.
- To determine if CDKN2a alterations correlate with MF development or progression.
Main Methods:
- Messenger RNA (mRNA) expression was analyzed using RT-PCR and dot blot hybridization in 20 MF patients.
- Immunohistochemistry was performed to assess p16INK4a protein levels in tumor cells.
- DNA mutational analysis was conducted to identify gene alterations.
Main Results:
- CDKN2a mRNA was undetectable in 25% of patients, intermediate in 65%, and high in 10%.
- p16INK4a protein expression inversely correlated with mRNA levels.
- No direct correlation was observed between clinicopathological features and molecular findings.
- No CDKN2a point mutations or minor deletions were detected in the analyzed patients.
Conclusions:
- The lack of CDKN2a expression in a subset of MF patients may contribute to the disease's pathogenesis.
- Absence of CDKN2a mRNA in MF is not associated with detectable point mutations or minor gene deletions.
- Further research is needed to elucidate the precise mechanisms underlying CDKN2a dysregulation in mycosis fungoides.